(rac)ibt6a

(Rac)-IBT6A is a racemate of IBT6A, an impurity of Ibrutinib that can be utilized in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.

(Rac)-IBT6A hydrochloride is a racemic mixture of IBT6A hydrochloride, an impurity of Ibrutinib, involved in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct [1]. IBT6A is related to Ibrutinib, a selective and irreversible Bruton's tyrosine kinase (Btk) inhibitor with an IC50 of 0.5 nM [2].

(Rac)-IBT6A hydrochloride is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM).

PF-4136309 (INCB8761, PF-04136309) is a highly effective and selective oral CCR2 antagonist with good bioavailability, with an IC50 value of 5.2 nM for human CCR2.

D-Luciferin 6′-methyl ether (6′-Methoxyluciferin; compound 19a) sodium serves as a potent inhibitor of the North American firefly Photinus pyralis (PpyLuc) luciferase, exhibiting an IC50 of 0.1 μM. As an analog of D-luciferin, this compound demonstrates non-specific interactions at the ATP- and luciferin-binding sites within the active site of PpyLuc [1].